The male patient had been enrolled in the ALPHA3 trial, in which Allogene is evaluating a novel CAR-T therapy for diffuse large B-cell lymphoma (DLBCL), according to Fierce Biotech.
The death occurred nearly two months after the patient received treatment, which included the experimental antibody ALLO-647 alongside standard lymphodepletion drugs. ...
Allogene discontinues investigational antibody following patient death
U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pivotal CAR-T trial.
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration